Publication date: 2024-02-23
In this clinical review, Dr. Patrick Nemechek discusses macular degeneration through the lens of his broader framework about neurodegenerative conditions and systemic inflammation. He emphasizes the functional importance of the macula—a region of the retina responsible for the majority of detailed vision—and describes macular degeneration as a deterioration of this critical tissue that is often detected in midlife or later by an ophthalmologist.
Dr. Nemechek also highlights why the eye can be clinically informative beyond vision itself. In his description, the retina represents brain tissue, and the eye is a unique location where arteries and veins can be seen three-dimensionally, offering clues that, in his view, relate to tissue health and inflammation.
What the macula is—and why degeneration matters
Dr. Nemechek explains that the macula is part of the retina and is highly concentrated in terms of visual function—he states that the majority of vision (about 90%) comes from the macula. In his framing, macular degeneration refers to progressive deterioration in this region, which can lead to noticeable visual issues or be identified during eye examination.
He further notes that, from a medical perspective, “the retina is actually our brain cells,” describing the cells lining the inside of the eyeball as brain tissue. Within the context of this video, that point supports his broader view that changes in retinal health can reflect neurological and systemic health considerations.
How Dr. Nemechek categorizes macular degeneration
In Dr. Nemechek’s clinical interpretation, macular degeneration fits within a category of neurodegenerative disorders. He explicitly groups it alongside conditions such as Alzheimer’s disease, Parkinson’s disease, and ALS (“Lou Gehrig’s disease”). In the framework discussed in the video, he attributes these neurodegenerative disorders to inflammation, stating that they are “driven by inflammation.”
He also underscores what he views as an underappreciated feature of the nervous system: a “remarkable capacity to recover.” In this discussion, that recovery potential is presented as relevant to retinal/visual neuro-recovery in macular degeneration.
What he reports seeing clinically on “the protocol” (early-stage cases)
Dr. Nemechek reports that he has seen improvement in a small group of patients with macular degeneration after implementing what he refers to as “the protocol.” He states that he has had “10–15 patients” with macular degeneration and that “when you put them on the protocol [it] goes away.” He characterizes these as earlier-stage patients who had vision affected and “clear degenerative signs.”
He adds an important boundary: these were not patients already receiving injections in the eye, and he says he cannot comment specifically on those more advanced situations because he has not tried the protocol in that group.
Elements he names in his protocol approach
In the video, Dr. Nemechek lists components he uses when applying his protocol in these cases, including:
- Addressing the gut (“fix their gut,” as he describes it)
- Continuous fish oil (he mentions “continuous” and references “Caron or… fish oil”)
- Olive oil
- VNS (vagus nerve stimulation), with a cycling VNS signal used for 1–2 hours per day in this age group
He also mentions that patients may use a transcutaneous neuromodulator for the ear, within the context of VNS.
The recovery timeline he describes
Dr. Nemechek describes a typical timeframe in his clinical experience: improvement may be visible by about 3–4 months (he references follow-up imaging showing improvement), and he states that “usually by 6–8 months it’s completely gone,” describing a “total” reversal in those early-stage cases. He concludes from this experience that macular degeneration is “a reversible condition,” and he attributes the driving factor to inflammation in his model.
Care logistics mentioned in the video
Dr. Nemechek notes that his clinic can help patients obtain items he referenced (such as the fish oil product he mentions and a transcutaneous neuromodulator for the ear). He describes a care model involving a single in-person visit with follow-ups conducted by Skype afterward.
Educational medical disclaimer: This article summarizes statements from a single video by Dr. Patrick Nemechek and is for educational purposes only. It is not medical advice and is not a substitute for care from an ophthalmologist or other qualified clinician. If you have vision changes or have been diagnosed with macular degeneration, seek individualized medical evaluation and discuss treatment options and safety considerations with your healthcare team.
